Forest Laboratories Inc (FRX.N) said on Tuesday it agreed to acquire Clinical Data Inc (CLDA.O) to add to its portfolio of drugs to treat depression. Forest, which makes the antidepressants Lexapro and Celexa, and Alzheimer's drug Namenda, would pay $30 a share in cash, plus additional payments of up to $6 a share if Clinical Data's recently approved antidepressant Viibryd achieved commercial milestones. Forest said it expects the transaction would dilute its earnings per share for the next three fiscal years. The transaction is not expected to affect the company's 2011 financial forecast. (Reporting by Toni Clarke, editing by Gerald E. McCormick)
Source
